Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-02-20 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
PUBLICATION OF THE 2024 ANNUAL RESULTS OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANKUANG ENERGY GROUP COMPANY LIMITED
Report Publication Announcement Classification · 1% confidence The document is a short exchange notice informing investors that Yancoal Australia (a subsidiary) has published its 2024 annual results announcement on ASX and HKEX, and provides a link for the full details. It does not contain the full report itself but simply announces the publication of that report. This matches the definition of a Report Publication Announcement (RPA).
2025-02-20 English
CONNECTED TRANSACTION IN RELATION TO THE DEEMED DISPOSAL OF 47.168% EQUITY INTERESTS IN DONGFANG ELECTRICAL
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement by a Hong Kong-listed issuer under the Listing Rules describing a connected transaction whereby a wholly owned subsidiary enters into a Capital Increase Agreement, resulting in a new equity subscription and the deemed disposal of part of its stake in a subsidiary. It focuses on the terms of the capital increase, shareholding ratios, valuation basis and regulatory implications under Chapter 14A. This is not an annual or interim report, earnings release, or AGM material. It is not simply notifying publication of a report, nor is it management changes or legal proceedings. The content clearly relates to a capital change (new share subscription and adjustment of registered capital) and change in shareholding interest, matching the “Share Issue/Capital Change” filing category (SHA).
2025-02-14 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES INCLUSION OF SUGEMALIMAB (CEJEMLY) AS FIRST-LINE COMBINATION THERAPY FOR NSCLC IN ESMO GUIDELINE
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement filed on the Hong Kong Stock Exchange disclosing that CStone’s drug sugemalimab has been included in an ESMO guideline. It contains forward-looking disclaimers and product/clinical updates but no financial results, dividend, rights issue, management changes, or other specialized content. It is not a financial report (10-K/IR/ER), meeting material (AGM, DVA), or other narrowly defined filing. This type of general corporate or regulatory announcement falls under the fallback category “Regulatory Filings” (RNS).
2025-02-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange FF301 monthly return detailing movements in authorised/issued share capital and share options (new shares issued), submitted under HKEX Listing Rules. It reports share capital changes rather than summarizing financial results or announcing a meeting. This aligns with the definition of Share Issue/Capital Change.
2025-02-06 English
Monthly Return
Regulatory Filings Classification · 1% confidence The document is a monthly return (Form FF301) filed with the Hong Kong Exchange detailing movements in registered and issued share capital and confirming no share repurchases or other capital changes for the period. It is a periodic regulatory compliance submission under the Exchange Listing Rules, not an announcement of a capital change event itself nor a financial report or presentation. There is no specific category for monthly listing rule returns, so it falls under the fallback “Regulatory Filings” category (RNS).
2025-02-06 English
VOLUNTARY ANNOUNCEMENT - CSTONE AND STEINCARES ENTER INTO STRATEGIC PARTNERSHIP TO MARKET SUGEMALIMAB IN LATIN AMERICA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by CStone Pharmaceuticals of a strategic licensing and commercialization partnership with SteinCares. It contains no financial results, regulatory filing of a report, share issuance, AGM materials, or director changes. It is a routine corporate news release that does not fit any specialized category (e.g., earnings, M&A, financing, board changes, dividends), so it falls into the fallback category for general regulatory announcements. Therefore, it should be classified as an RNS.
2025-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.